pralidoxime

pralidoxime
Name	pralidoxime
Synon	2-PAM; pralidoxime chloride
Class	Oxime; cholinesterase reactivator
Routes of administration	Intravenous; intramuscular; topical (research)
Elimination half-life	~1–2 hours
Excretion	Renal

pralidoxime

Pralidoxime is an oxime compound used as an antidote for organophosphate and certain carbamate poisoning, acting to reactivate inhibited acetylcholinesterase. It is deployed in emergency medicine, toxicology, and military medicine settings alongside anticholinergic therapy and supportive care. Use has been guided by clinical practice in contexts such as industrial pesticide exposure, nerve agent incidents, and mass casualty planning.

Medical uses

Pralidoxime is indicated for acute poisoning due to organophosphate insecticides and nerve agents encountered in incidents related to Bhopal disaster, Tokyo subway sarin attack, Iran–Iraq War, Gulf War, and industrial accidents involving compounds similar to parathion, malathion, tabun, sarin, and soman. In hospital settings such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, and Royal Infirmary of Edinburgh, it is used together with atropine in protocols derived from guidelines by organizations like World Health Organization, Centers for Disease Control and Prevention, and European Medicines Agency. Emergency medical services in cities including New York City, London, Tokyo, Paris, and Sydney maintain stocks in case of pesticide mass exposure or chemical weapon events. Pralidoxime has also been employed in field use by armed forces including units of the United States Army, British Army, and Israeli Defense Forces during chemical exposure incidents.

Mechanism of action

Pralidoxime reactivates acetylcholinesterase inhibited by phosphorylation from organophosphate compounds, reversing the accumulation of acetylcholine at synapses implicated in crises noted during incidents like the Sarin attack in Matsumoto and historical chemical weapon deployments in World War I. The oxime moiety nucleophilically attacks the phosphorylated serine residue on the enzyme, displacing the organophosphate and restoring catalytic activity, a concept central to discussions at scientific meetings such as those at the Royal Society and published in journals affiliated with institutions like Harvard University, Stanford University, and University of Oxford. The rate of reactivation depends on the specific organophosphate (examples include soman which undergoes rapid ageing) and has been a focus of research at laboratories like Los Alamos National Laboratory and Sandia National Laboratories.

Pharmacology

Pralidoxime is a quaternary ammonium compound with limited ability to cross the blood–brain barrier, influencing its central nervous system efficacy compared with peripheral effects studied at research centers such as National Institutes of Health and Salk Institute. Pharmacokinetic parameters including renal excretion have been documented in clinical pharmacology texts used at Columbia University, University of California, San Francisco, and Karolinska Institute. The half-life approximates 1–2 hours with variations reported in studies from hospitals such as Cleveland Clinic and Royal Melbourne Hospital. Interdisciplinary work involving toxicologists from Johns Hopkins Bloomberg School of Public Health, Imperial College London, and University of Toronto has examined pralidoxime distribution, metabolism, and comparative efficacy to experimental reactivators developed at institutions like MIT and ETH Zurich.

Administration and dosage

Standard regimens combine pralidoxime with atropine; protocols used by American Academy of Clinical Toxicology and military manuals from NATO recommend intravenous bolus followed by infusion or repeated intramuscular injections depending on severity and logistics. Typical adult dosing strategies described in emergency formularies at Beth Israel Deaconess Medical Center and Toronto General Hospital include 30 mg/kg to 50 mg/kg IV bolus or fixed doses such as 1–2 g IV, repeated as needed, with infusion rates individualized per guidance from Royal College of Physicians and regional poison centers like National Poisons Information Service and Poisons Information Centre, Australia. Pediatric dosing follows weight-based calculations as advised by agencies including American Academy of Pediatrics.

Adverse effects

Reported adverse effects in clinical case series from centers like Guy's and St Thomas' NHS Foundation Trust and Hôpital Pitié-Salpêtrière include hypertension, tachycardia, dizziness, visual disturbances, neuromuscular weakness, and local injection site pain. Severe reactions such as rhabdomyolysis and respiratory compromise have been described in case reports published by clinicians at Mount Sinai Health System and Zuckerberg San Francisco General Hospital when used in high doses or in vulnerable populations. Monitoring guidelines by organizations like European Resuscitation Council and American Heart Association recommend cardiorespiratory support during administration.

Interactions

Pralidoxime is administered concomitantly with anticholinergics such as atropine and supportive agents used in critical care at institutions like Cedars-Sinai Medical Center and St Thomas' Hospital. Interactions with neuromuscular blocking agents used during anesthesia in centers including Mayo Clinic and John Radcliffe Hospital require coordination with anesthesiology services. Pharmacodynamic interactions have been evaluated alongside enzyme reactivators studied at NIH and pharmacologists at University of Edinburgh.

History and development

Research into oximes including pralidoxime originated in the early-to-mid 20th century with contributions from chemists and toxicologists associated with universities such as University of Birmingham, University of Manchester, University of Cambridge, and University of Glasgow. Development accelerated during periods of chemical warfare research in contexts such as World War II and Cold War-era programs at national laboratories like Edgewood Arsenal and academic collaborations with University of Iowa. Key clinical experiences came from pesticide poisoning outbreaks in regions including India, Bangladesh, and Sri Lanka, prompting trials and policy discussions hosted by WHO and research published via institutions including Johns Hopkins and University of Sydney.

Regulatory status and availability

Pralidoxime salts are approved and stocked for medical use in many countries with regulatory oversight by agencies like the Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Therapeutic Goods Administration, and national authorities in countries including India and Brazil. Availability in emergency preparedness stockpiles is maintained by organizations such as Strategic National Stockpile and national defense inventories including U.S. Department of Defense and Ministry of Defence (United Kingdom). Clinical guidance and formulary listings appear in hospitals and poison control centers worldwide including Karolinska University Hospital and Singapore General Hospital.

Category:Antidotes